Kangfang Bio PD-1 sold about 300 million yuan in the first half of the year, and PD-1/CTLA-4 double antibody received nearly 100 million yuan in advance receipts

On August 23, Kangfang Bio released the first half of the performance report, with a total revenue of 163 million yuan, an increase of 26.

As an innovative pharmaceutical company that landed on the Hong Kong Stock Exchange with 18A, Kangfang Bio currently has two main commercial products, namely PD-1 monoclonal antibody Pisapril approved for listing in Q4 2021 and PD-1/CTLA-4 dual-antibody new drug cardulin,

Among them, PD-1 monoclonal antibody Pyampli still achieved good results in the context of the obvious decline in the overall sales of domestic PD-1 in the first half of the year, and the sales amount of products in the first half of the year was close to 300 million yuan

The PD-1/CTLA-4 dual antibody new drug cardulinelli was successfully approved for marketing in June this year, and it is also the first tumor dual immune checkpoint double antibody

At the same time, Kangfang Bio has begun to submit relevant materials to the National Medical Insurance Bureau for the 2022 innovative drug medical insurance negotiations, if the negotiation is successful, it will reduce the burden of medication for patients, rapidly and widely improve the accessibility of drugs, and bring treatment hope

Among the pipeline assets of Kangfang Biotech, a total of 13 pipelines with 5 major products are in the critical/III stage

The registered/phase III clinical studies of the PD-1/CTLA-4 dual antibody (cardulinizumab), which involve at least four major indications such as first-line cervical cancer, first-line gastric cancer, and hepatocellular carcinoma, have been efficiently advanced, of which first-line cervical cancer has been enrolled

Two clinical studies of the PD-1/VEGF duo antibody (evosimab, R&D code AK112) also entered the phase III phase III phase, including phase III clinical studies of AK112 combined with chemotherapy for the treatment of EGFR-TKI-resistant EGFR mutations in advanced NSQ-NSCLC and phase III clinical studies

If carried out successfully, it will be the first bispecific antibody new drug

In the non-oncology field, the company also has 2 new drugs that are about to enter the harvest period

In terms of production capacity, Kangfang Bio has a total operating capacity of 31,500 liters and has a stable capacity expansion plan to meet future clinical and commercial needs

As of June 30, 2022, Kangfang Bio's current assets were RMB2.

The number of employees in Kangfang Bio has almost doubled compared with the same period in 2021, reaching 2289 people, of which nearly 800 are in R&D and clinical, and a sales and marketing team